AU2019377115A1 - Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear - Google Patents
Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear Download PDFInfo
- Publication number
- AU2019377115A1 AU2019377115A1 AU2019377115A AU2019377115A AU2019377115A1 AU 2019377115 A1 AU2019377115 A1 AU 2019377115A1 AU 2019377115 A AU2019377115 A AU 2019377115A AU 2019377115 A AU2019377115 A AU 2019377115A AU 2019377115 A1 AU2019377115 A1 AU 2019377115A1
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- acid substitutions
- amino acids
- cell target
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756953P | 2018-11-07 | 2018-11-07 | |
| US62/756,953 | 2018-11-07 | ||
| US201962888093P | 2019-08-16 | 2019-08-16 | |
| US62/888,093 | 2019-08-16 | ||
| PCT/US2019/060328 WO2020097372A1 (en) | 2018-11-07 | 2019-11-07 | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019377115A1 true AU2019377115A1 (en) | 2021-05-20 |
Family
ID=70611216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019377115A Pending AU2019377115A1 (en) | 2018-11-07 | 2019-11-07 | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20230056182A1 (https=) |
| EP (2) | EP4063510A1 (https=) |
| JP (2) | JP2022506613A (https=) |
| CN (2) | CN118497276A (https=) |
| AU (1) | AU2019377115A1 (https=) |
| CA (1) | CA3119065A1 (https=) |
| WO (1) | WO2020097372A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019530737A (ja) | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| US12054724B2 (en) | 2018-04-10 | 2024-08-06 | President And Fellows Of Harvard College | AAV vectors encoding clarin-1 or GJB2 and uses thereof |
| US11660353B2 (en) | 2018-04-27 | 2023-05-30 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| CN119410636A (zh) | 2018-04-27 | 2025-02-11 | 分贝治疗公司 | 肌球蛋白15启动子及其用途 |
| AU2020218547A1 (en) | 2019-02-08 | 2021-08-26 | Decibel Therapeutics, Inc. | Myosin 15 promoters and uses thereof |
| EP3921032A4 (en) | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS |
| CA3159549A1 (en) | 2019-10-30 | 2021-05-06 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| JP7807380B2 (ja) | 2020-02-21 | 2026-01-27 | アコーオス インコーポレイテッド | ヒト対象において非加齢関連聴力障害を処置するための組成物および方法 |
| EP4164695A4 (en) * | 2020-05-13 | 2024-06-05 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS |
| US20240016955A1 (en) * | 2020-09-14 | 2024-01-18 | President And Fellows Of Harvard College | Dual-aav vector delivery of pcdh15 and uses thereof |
| JP2023541443A (ja) * | 2020-09-14 | 2023-10-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | GJB2をコードする組換えアデノ随伴ウイルス(rAAV)およびその使用。 |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| AU2021376225A1 (en) * | 2020-11-06 | 2023-06-22 | Eli Lilly And Company | Variant adeno-associated virus (aav)capsid polypeptides and gene therapeutics thereof for treatment of hearing loss |
| IL303317A (en) * | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023007800A (es) | 2020-12-29 | 2023-07-11 | Akouos Inc | Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1. |
| US20220267795A1 (en) * | 2021-02-24 | 2022-08-25 | Kinase Pharma Inc. | Compositions and methods for regulating production of an angiogensis inhibitor |
| EP4473011A1 (en) * | 2022-02-02 | 2024-12-11 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| KR20250080886A (ko) * | 2022-09-30 | 2025-06-05 | 데시벨 테라퓨틱스, 인크. | Slc26a4 조절 요소 및 이의 용도 |
| WO2025179016A1 (en) * | 2024-02-20 | 2025-08-28 | Skylark Bio, Inc. | Recombinant adeno associated virus and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0928202A4 (en) * | 1996-09-25 | 2001-09-05 | Cell Genesys Inc | NON-INVASIVE ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTORS |
| EP1082445A2 (en) * | 1998-05-27 | 2001-03-14 | Cell Genesys, Inc. | Adeno-associated viral vector-mediated expression of factor viii activity |
| WO2011075838A1 (en) * | 2009-12-21 | 2011-06-30 | Audigen Inc. | Method of treating or preventing hearing loss |
| CA2890061A1 (en) * | 2012-12-04 | 2014-06-12 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
| CA2909733C (en) * | 2013-04-18 | 2023-10-17 | Fondazione Telethon | Effective delivery of large genes by dual aav vectors |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| TWI813532B (zh) * | 2015-06-18 | 2023-09-01 | 美商博得學院股份有限公司 | 降低脱靶效應的crispr酶突變 |
| SG11201804814YA (en) * | 2015-12-11 | 2018-07-30 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| WO2017136764A1 (en) * | 2016-02-05 | 2017-08-10 | The General Hospital Corporation | Hybrid system for efficient gene delivery to cells of the inner ear |
| WO2017181021A1 (en) * | 2016-04-15 | 2017-10-19 | Regenxbio Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| JP2019530737A (ja) * | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
| KR102746901B1 (ko) * | 2017-03-03 | 2024-12-26 | 옵시디안 테라퓨틱스, 인크. | Cd19 조성물 및 면역요법을 위한 방법 |
-
2019
- 2019-11-07 CN CN202410531995.8A patent/CN118497276A/zh active Pending
- 2019-11-07 CN CN201980082439.4A patent/CN113853437A/zh active Pending
- 2019-11-07 JP JP2021524060A patent/JP2022506613A/ja active Pending
- 2019-11-07 WO PCT/US2019/060328 patent/WO2020097372A1/en not_active Ceased
- 2019-11-07 EP EP22155160.9A patent/EP4063510A1/en not_active Withdrawn
- 2019-11-07 EP EP19881503.7A patent/EP3880826A4/en not_active Withdrawn
- 2019-11-07 US US17/291,931 patent/US20230056182A1/en not_active Abandoned
- 2019-11-07 CA CA3119065A patent/CA3119065A1/en active Pending
- 2019-11-07 AU AU2019377115A patent/AU2019377115A1/en active Pending
-
2024
- 2024-03-25 JP JP2024048210A patent/JP2024086735A/ja active Pending
- 2024-08-15 US US18/806,641 patent/US20250041457A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020097372A8 (en) | 2021-04-29 |
| US20230056182A1 (en) | 2023-02-23 |
| US20250041457A1 (en) | 2025-02-06 |
| EP4063510A1 (en) | 2022-09-28 |
| JP2024086735A (ja) | 2024-06-28 |
| CN113853437A (zh) | 2021-12-28 |
| JP2022506613A (ja) | 2022-01-17 |
| EP3880826A1 (en) | 2021-09-22 |
| EP3880826A4 (en) | 2022-08-24 |
| CN118497276A (zh) | 2024-08-16 |
| CA3119065A1 (en) | 2020-05-14 |
| WO2020097372A1 (en) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250041457A1 (en) | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear | |
| CN114555621B (zh) | 键修饰的寡聚化合物及其用途 | |
| AU2019360182B2 (en) | Methods for targeted insertion of DNA in genes | |
| KR101708544B1 (ko) | 세포 증식 질환을 분석하기 위한 방법 및 핵산 | |
| AU2023274083A1 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| ES2744098T3 (es) | Composiciones y sus usos dirigidos a la huntingtina | |
| KR102526525B1 (ko) | 타우 발현 조절 조성물 | |
| KR102046668B1 (ko) | 암 대상자의 예후를 결정하기 위한 방법 및 핵산 | |
| KR20220012230A (ko) | 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물 | |
| RU2768285C1 (ru) | Олигонуклеотиды для модуляции экспрессии тау-белка | |
| CA2941594A1 (en) | Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof | |
| KR20170086027A (ko) | 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법 | |
| US20220395582A1 (en) | Compositions and methods of inducing differentiation of a hair cell | |
| AU2016325030A1 (en) | Novel biomarkers and methods of treating cancer | |
| KR20130123357A (ko) | 저산소증과 관련된 질환의 진단방법 및 키트 | |
| WO2006022629A1 (en) | Methods of identifying risk of type ii diabetes and treatments thereof | |
| DK1939287T3 (en) | Method of gene transfer specific to a trophectodermal cell | |
| KR102647919B1 (ko) | App 돌연변이 세포 및 이의 이용 | |
| WO2018209358A2 (en) | Systemic delivery of polypeptides | |
| WO2006022638A1 (en) | Methods for identifying risk of type ii diabetes and treatments thereof | |
| TW202221014A (zh) | 用於減少app表現之化合物及方法 | |
| CA2887830A1 (en) | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | |
| KR20130024137A (ko) | 묘안 증후군 진단용 마이크로어레이 및 키트 |